Biotest indemnification claim now completely gone. Another $5.7 in the company's treasury and another uncertainty resolved.

I agree that the real issue now, if the company is to be sold is getting a decent price. I surmise they could get, and have been offered around 6, but will, justifiably, hold out for north of 8. The NH grant, the GSK deal and the withdrawal of the Biotest claim is worth $40mil. additional cash resource to the company. Favorable results on the trials would make the company, with its cash and pipeline worth a significant multiple of 8, but at a risk and loss of time sufficient to justify a sale north of 8.

By the way, we are patient longs in this stock.